title: The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
abstract: OBJECTIVE
  To analyse the prognostic value of vascular endothelial growth factor (VEGF) in men with clinically localized prostate cancer.
  
  
  METHODS
  Paraffin wax-embedded sections from the radical prostatectomy (RP) specimens of 40 men operated for clinically localized prostate cancer were used to build tissue microarrays. Of these patients, 17 had cancer progression and bone metastases after RP (group 1), and 23 remained free-of-tumour recurrence after RP (group 2). VEGF-A expression was examined in the RP specimens using immunohistochemistry.
  
  
  RESULTS
  The groups had similar tumour characteristics in terms of prostate-specific antigen level, Gleason score, and pathological stage. VEGF-A expression was significantly higher in group 1 than in group 2 (P=0.046). In logistic regression analysis, VEGF-A expression was the most significant predictive factor of cancer progression after RP.
  
  
  CONCLUSIONS
  VEGF-A expression in prostate cancer tissue is associated with the risk of cancer progression after RP. These results suggest that VEGF-A expression has a prognostic impact in clinically localized prostate cancer.
authors: Department of Urology, Cochin Hospital, Paris, France. michael.peyromaure@cch.aphp.fr
authors: Michaël
authors: M
authors: Peyromaure
authors: Philippe
authors: P
authors: Camparo
authors: Cécile
authors: C
authors: Badoual
authors: Aurélien
authors: A
authors: Descazeaud
authors: Anh-Tuan
authors: AT
authors: Dinh-Xuan
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001859:Bone Neoplasms / Q000556:secondary; D018450:Disease Progression; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D046228:Microarray Analysis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011237:Predictive Value of Tests; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery; D012044:Regression Analysis; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D042461:Vascular Endothelial Growth Factor A; D017430:Prostate-Specific Antigen